Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

MoreLess

Year of publication:	2014
Authors:	Gulácsi, László ; Rencz, Fanni ; Péntek, Márta ; Brodszky, Valentin ; Lopert, Ruth ; Hevér, Noémi ; Baji, Petra
Published in:	The European Journal of Health Economics. - Springer. - Vol. 15.2014, 1, p. 27-34
Publisher:	Springer
Subject:	Cost-utility \| Inflammatory conditions \| Biologicals \| Central and Eastern Europe \| HTA \| Reimbursement \| I 110 \| I 130

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10010993927